Analysts at StockNews.com assumed coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Get Free Report) in a report issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.
RedHill Biopharma Trading Down 1.6 %
NASDAQ RDHL opened at $0.35 on Tuesday. RedHill Biopharma has a 52 week low of $0.26 and a 52 week high of $3.28. The firm has a 50 day moving average of $0.41 and a two-hundred day moving average of $0.53.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in RedHill Biopharma stock. Gagnon Securities LLC boosted its position in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) by 32.1% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 118,360 shares of the biotechnology company’s stock after acquiring an additional 28,771 shares during the period. Gagnon Securities LLC owned about 0.40% of RedHill Biopharma worth $63,000 as of its most recent SEC filing. Institutional investors and hedge funds own 7.20% of the company’s stock.
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Recommended Stories
- Five stocks we like better than RedHill Biopharma
- Breakout Stocks: What They Are and How to Identify Them
- Food Processing Company Stock Gets Fried by Recall: Time to Buy
- What is an Earnings Surprise?
- Entertainment Stock Offers A Rare and Tempting Entry Opportunity
- Canada Bond Market Holiday: How to Invest and Trade
- Will China’s Interest Rate Cuts Ignite a Rally for This Stock?
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.